Convatec Investors - CTEC

Convatec Investors - CTEC

Buy
Sell
Best deals to access real time data!
Silver
Monthly Subscription
for only
£17.37
Level 2 Basic
Monthly Subscription
for only
£62.08
UK/US Silver
Monthly Subscription
for only
£30.59
VAT not included
Stock Name Stock Symbol Market Stock Type Stock ISIN Stock Description
Convatec Group Plc CTEC London Ordinary Share GB00BD3VFW73 ORD 10P
  Price Change Price Change % Stock Price Last Trade
-1.05 -0.52% 199.15 16:29:58
Open Price Low Price High Price Close Price Previous Close
199.70 198.10 202.80 199.15 200.20
more quote information »
Industry Sector
HEALTH CARE EQUIPMENT & SERVICES

Top Investor Posts

DateSubject
29/7/2019
12:58
ny boy: Gap to fill on the breakout to 188/190p area ConvaTec Group Plc shows strong development within a rising trend channel in the medium long term. Rising trends indicate that the company experiences positive development and that buy interest among investors is increasing. The price has had a strong fall after the negative signal from rectangle formation at the break down through the support at 188. The objective at 152 is now met, but the formation signals further development in the same direction. The stock has broken up through the resistance at pence 147. This predicts a further rise. In case of negative reactions, there will now be support at pence 147. The stock is overall assessed as technically positive for the medium long term. Recommendation one to six months: Positive
02/4/2019
08:39
robow: from Citywire 26 Mar 19 AJ Bell: Convatec in need of a shake-up A management shake-up at medical equipment maker Convatec (CTEC) could be the start of a new way of thinking that could benefit investors, says AJ Bell. Convatec has poached Genus’ boss Karim Bitar to be its new chief executive to lead its turnaround effort just as the former is also losing its chairman and deputy chairman. ‘Convatec desperately needs a new lease of life as it has been a serial disappointment for most of its time as a listed business,’ said analyst Russ Mould. Last month, the group announced plans to invest $150 million over three years and Mould said ‘the scale of such investment was significantly greater than expected, despite having scope to deliver $120 million in annual savings by 2023, as well as improvements in revenue growth and profit margins’.
16/10/2018
00:32
philanderer: Lex Column: 'ConvaTec: scar issue' Medical products group needs more time to heal itself after investors were bloodied https://www.ft.com/content/07bc74d8-d04d-11e8-a9f2-7574db66bcd5
15/10/2018
20:46
cantrememberthis2: Despite the warning and its cautious stance on the stock, RBC said the share price reset has gone too far and highlighted the fact that Convatec is still a cash generative business with attractive qualities. "We would remind investors that Convatec is still a highly cash generative business, and at the current share price is generating a free cash flow yield of over 7%, with a dividend yield of 3%," it said. "With the performance wanting we would hope all options are now on the table to maximise shareholder value."
24/7/2018
14:32
hazl: Ah, there was a problem described by the FT in February this year,that they thought would affect first half but improve by second half of the year. Hurricanes in the DOMINICAN REPUBLIC...where they make some of their products,held them back. I think it looks like this is not only in recovery but attracting interest,not only in it's products,but as robow points out,investors....worthy investors! IMO
24/7/2018
14:19
hazl: Perhaps there will be more reports out now on them after this good news. I found this one from back in February where they thought they were a good buy then by the looks of it. 'Buy Convatec for recovery, says Share Centre Strong full-year results from medical technology company Convatec (CTEC) boosted the shares but they are still a ‘long way’ from their highs and remain a buying opportunity, believes The Share Centre. Analyst Helal Miah retained his ‘buy’ recommendation for ‘investors seeking a recovery potential and willing to accept a higher level of risk’ following last week’s results saw the shares rally 7%. They dipped 1%, or 2.3p, to 213p on Monday. ‘Overall the group has shown some positive progress, it operates in a defensive market with significant growth opportunities,’; said Miah. ‘While the shares are a long way off from its highs, we believe this is a growth opportunity to pick up these shares for the long term.’ He added that the underlying market for Convatec is ‘defensive in nature, but growth opportunities exist from ageing populations, the increased prevalence of chronic conditions, and the fact that patients are living longer with these conditions’
20/2/2018
08:12
robow: Buy Convetec for recovery,says Share Centre Strong full-year results from medical technology company Convatec (CTEC) boosted the shares but they are still a ‘long way’ from their highs and remain a buying opportunity, believes The Share Centre. Analyst Helal Miah retained his ‘buy’ recommendation for ‘investors seeking a recovery potential and willing to accept a higher level of risk’ following last week’s results saw the shares rally 7%. They dipped 1%, or 2.3p, to 213p on Monday. ‘Overall the group has shown some positive progress, it operates in a defensive market with significant growth opportunities,’; said Miah. ‘While the shares are a long way off from its highs, we believe this is a growth opportunity to pick up these shares for the long term.’ He added that the underlying market for Convatec is ‘defensive in nature, but growth opportunities exist from ageing populations, the increased prevalence of chronic conditions, and the fact that patients are living longer with these conditions’.
16/10/2017
15:02
pugugly: Private investors stuffed yet again - Take care when Private Equity houses sell down - They normally know what they are doing and have seen rough water in the near or middle future (imo)
15/9/2017
17:18
gswredland: So what are the main worries for investors guys?
09/8/2017
15:55
modform: It's a shame that the company has so much debt that it needs 35% of its profit to service the interest. The company has a moat so will hopefully reward the patient investors
ADVFN Advertorial
Your Recent History
LSE
CTEC
Convatec
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210412 03:57:09